SUNDANCE BIOSCIENCES ANNOUNCES FIRST PATIENT DOSED IN U.S. PHASE 2 CLINICAL TRIAL OF SUN-627 FOR PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS)

Reuters · 3d ago

Please log in to view news